Drug Profile
Ontamalimab - Takeda
Alternative Names: PF-00547659; PF-547659; SHP-647; TAK-647Latest Information Update: 08 Feb 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Takeda
- Class Anti-inflammatories; Hepatoprotectants; Monoclonal antibodies
- Mechanism of Action Inflammation mediator inhibitors; MADCAM1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
- Discontinued Crohn's disease; Ulcerative colitis
Most Recent Events
- 13 Dec 2023 Takeda completes the phase III trial in Crohn's Disease in US, Argentina, Australia, Austria, Belgium, Bosnia-Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, Estonia, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Lebanon, Lithuania, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Switzerland, Turkey, Ukraine, and United Kingdom (NCT03283085)
- 13 Dec 2023 Takeda completes the phase III trial in Ulcerative Colitis in US, Argentina, Australia, Austria, Belgium, Bosnia-Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, Estonia, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Lebanon, Lithuania, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Switzerland, Turkey, Ukraine, and United Kingdom (NCT03283085)
- 20 Jun 2023 Phase-I clinical trials in Non-alcoholic steatohepatitis (SC) (Takeda pipeline, June 2023)